Do analysts prefer ETOR or HQL?

eToro Group currently has a consensus target price of $49.56, indicating a potential upside of 87.74%. Given eToro Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe eToro Group is more favorable than abrdn Life Sciences Investors. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eToro Group 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.56 abrdn Life Sciences Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ETOR or HQL?

eToro Group has higher revenue and earnings than abrdn Life Sciences Investors. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eToro Group $11.98B 0.18 $215.70M $2.66 9.92 abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Which has better earnings & valuation, RVT or HQL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royce Small-Cap Trust N/A N/A N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is RVT or HQL more profitable?

Company Net Margins Return on Equity Return on Assets Royce Small-Cap Trust N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

Do analysts recommend TOP or HQL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TOP Financial Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 abrdn Life Sciences Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, TOP or HQL?

abrdn Life Sciences Investors has lower revenue, but higher earnings than TOP Financial Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TOP Financial Group $4.47M 413.04 -$1.17M -$0.02 N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is TOP or HQL more profitable?

Company Net Margins Return on Equity Return on Assets TOP Financial Group N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

Which has better earnings and valuation, TY or HQL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tri Continental N/A N/A N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is TY or HQL more profitable?

Company Net Margins Return on Equity Return on Assets Tri Continental N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

Which has higher valuation & earnings, HQL or USA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio abrdn Life Sciences Investors N/A N/A N/A N/A N/A Liberty All-Star Equity Fund $78.85M 23.00 N/A N/A N/A

Is HQL or USA more profitable?

Company Net Margins Return on Equity Return on Assets abrdn Life Sciences Investors N/A N/A N/A Liberty All-Star Equity Fund N/A N/A N/A

abrdn Life Sciences Investors (HQL) Competitors

$17.55 -0.02 (-0.09%)

Closing price 03:58 PM Eastern

Extended Trading

$17.55 +0.00 (+0.03%)

As of 04:15 PM Eastern

Compare

HQL vs. ETOR, RVT, TOP, TY, and USA

Should you buy abrdn Life Sciences Investors stock or one of its competitors? abrdn Life Sciences Investors's main competitors and comparable companies include eToro Group (ETOR), Royce Small-Cap Trust (RVT), TOP Financial Group (TOP), Tri Continental (TY), and Liberty All-Star Equity Fund (USA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "capital markets" industry.

How does abrdn Life Sciences Investors compare to eToro Group?

eToro Group (NASDAQ:ETOR) and abrdn Life Sciences Investors (NYSE:HQL) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

eToro Group has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

eToro Group currently has a consensus target price of $49.56, indicating a potential upside of 87.74%. Given eToro Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe eToro Group is more favorable than abrdn Life Sciences Investors.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eToro Group	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.56
abrdn Life Sciences Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, eToro Group had 3 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 3 mentions for eToro Group and 0 mentions for abrdn Life Sciences Investors. abrdn Life Sciences Investors' average media sentiment score of 0.00 beat eToro Group's score of -0.06 indicating that abrdn Life Sciences Investors is being referred to more favorably in the news media.

Company	Overall Sentiment
eToro Group	Neutral
abrdn Life Sciences Investors	Neutral

eToro Group has a net margin of 2.17% compared to abrdn Life Sciences Investors' net margin of 0.00%. eToro Group's return on equity of 20.26% beat abrdn Life Sciences Investors' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eToro Group	2.17%	20.26%	15.36%
abrdn Life Sciences Investors	N/A	N/A	N/A

eToro Group has higher revenue and earnings than abrdn Life Sciences Investors.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eToro Group	$11.98B	0.18	$215.70M	$2.66	9.92
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

Summary

eToro Group beats abrdn Life Sciences Investors on 9 of the 12 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Royce Small-Cap Trust?

Royce Small-Cap Trust (NYSE:RVT) and abrdn Life Sciences Investors (NYSE:HQL) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Royce Small-Cap Trust has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

25.6% of Royce Small-Cap Trust shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 0.1% of Royce Small-Cap Trust shares are owned by company insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Royce Small-Cap Trust pays an annual dividend of $1.48 per share and has a dividend yield of 8.6%. abrdn Life Sciences Investors pays an annual dividend of $2.24 per share and has a dividend yield of 12.8%.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royce Small-Cap Trust	N/A	N/A	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

In the previous week, Royce Small-Cap Trust had 5 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 5 mentions for Royce Small-Cap Trust and 0 mentions for abrdn Life Sciences Investors. Royce Small-Cap Trust's average media sentiment score of 1.16 beat abrdn Life Sciences Investors' score of 0.00 indicating that Royce Small-Cap Trust is being referred to more favorably in the media.

Company	Overall Sentiment
Royce Small-Cap Trust	Positive
abrdn Life Sciences Investors	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Royce Small-Cap Trust	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

Summary

Royce Small-Cap Trust and abrdn Life Sciences Investors tied by winning 3 of the 6 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to TOP Financial Group?

TOP Financial Group (NASDAQ:TOP) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TOP Financial Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
abrdn Life Sciences Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, TOP Financial Group had 5 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 5 mentions for TOP Financial Group and 0 mentions for abrdn Life Sciences Investors. TOP Financial Group's average media sentiment score of 0.38 beat abrdn Life Sciences Investors' score of 0.00 indicating that TOP Financial Group is being referred to more favorably in the media.

Company	Overall Sentiment
TOP Financial Group	Neutral
abrdn Life Sciences Investors	Neutral

0.3% of TOP Financial Group shares are held by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are held by institutional investors. 10.1% of abrdn Life Sciences Investors shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

abrdn Life Sciences Investors has lower revenue, but higher earnings than TOP Financial Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TOP Financial Group	$4.47M	413.04	-$1.17M	-$0.02	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
TOP Financial Group	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

TOP Financial Group has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

TOP Financial Group beats abrdn Life Sciences Investors on 4 of the 7 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Tri Continental?

Tri Continental (NYSE:TY) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Tri Continental pays an annual dividend of $1.14 per share and has a dividend yield of 3.3%. abrdn Life Sciences Investors pays an annual dividend of $2.24 per share and has a dividend yield of 12.8%.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tri Continental	N/A	N/A	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

10.2% of Tri Continental shares are held by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are held by institutional investors. 8.7% of Tri Continental shares are held by company insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tri Continental has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Tri Continental had 1 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 1 mentions for Tri Continental and 0 mentions for abrdn Life Sciences Investors. Tri Continental's average media sentiment score of 1.17 beat abrdn Life Sciences Investors' score of 0.00 indicating that Tri Continental is being referred to more favorably in the media.

Company	Overall Sentiment
Tri Continental	Positive
abrdn Life Sciences Investors	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Tri Continental	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

Summary

Tri Continental and abrdn Life Sciences Investors tied by winning 3 of the 6 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

abrdn Life Sciences Investors (NYSE:HQL) and Liberty All-Star Equity Fund (NYSE:USA) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Liberty All-Star Equity Fund had 1 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 1 mentions for Liberty All-Star Equity Fund and 0 mentions for abrdn Life Sciences Investors. abrdn Life Sciences Investors' average media sentiment score of 0.00 equaled Liberty All-Star Equity Fund'saverage media sentiment score.

Company	Overall Sentiment
abrdn Life Sciences Investors	Neutral
Liberty All-Star Equity Fund	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A
Liberty All-Star Equity Fund	$78.85M	23.00	N/A	N/A	N/A

32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 9.9% of Liberty All-Star Equity Fund shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Comparatively, 0.1% of Liberty All-Star Equity Fund shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
abrdn Life Sciences Investors	N/A	N/A	N/A
Liberty All-Star Equity Fund	N/A	N/A	N/A

abrdn Life Sciences Investors has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Liberty All-Star Equity Fund has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

abrdn Life Sciences Investors pays an annual dividend of $2.24 per share and has a dividend yield of 12.8%. Liberty All-Star Equity Fund pays an annual dividend of $0.67 per share and has a dividend yield of 11.4%.

Summary

abrdn Life Sciences Investors and Liberty All-Star Equity Fund tied by winning 3 of the 6 factors compared between the two stocks.

Get abrdn Life Sciences Investors News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HQL vs. The Competition

Export

Metric	abrdn Life Sciences Investors	Capital Markets Industry	Finance Sector	NYSE Exchange
Market Cap	$533.54M	$5.12B	$13.22B	$22.79B
Dividend Yield	12.67%	7.58%	6.04%	3.72%
P/E Ratio	N/A	30.17	24.77	27.88
Price / Sales	N/A	1,144.69	479.72	14.73
Price / Cash	N/A	47.69	43.98	36.95
Price / Book	N/A	3.47	2.69	4.67
Net Income	N/A	$415.67M	$1.32B	$1.07B
7 Day Performance	-6.05%	-0.63%	-0.59%	0.28%
1 Month Performance	-14.58%	-3.07%	-3.67%	-5.95%
1 Year Performance	11.26%	10.68%	9.91%	5.52%

abrdn Life Sciences Investors Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HQL abrdn Life Sciences Investors	N/A	$17.55 -0.1%	N/A	+11.9%	$533.54M	N/A	N/A	N/A
ETOR eToro Group	4.7229 of 5 stars	$25.56 -0.5%	$49.56 +93.9%	-35.9%	$2.12B	$13.84B	9.60	1,520	Analyst Forecast
RVT Royce Small-Cap Trust	N/A	$17.02 -0.6%	N/A	+4.9%	$2.11B	$88.69M	N/A	50	Positive News
TOP TOP Financial Group	0.2253 of 5 stars	$15.13 +1.3%	N/A	+139.7%	$1.84B	$4.72M	N/A	30
TY Tri Continental	N/A	$34.48 +0.5%	N/A	+0.9%	$1.84B	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HQL) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

abrdn Life Sciences Investors (HQL) Competitors

HQL vs. ETOR, RVT, TOP, TY, and USA

How does abrdn Life Sciences Investors compare to eToro Group?

Summary

How does abrdn Life Sciences Investors compare to Royce Small-Cap Trust?

Summary

How does abrdn Life Sciences Investors compare to TOP Financial Group?

Summary

How does abrdn Life Sciences Investors compare to Tri Continental?

Summary

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQL vs. The Competition

abrdn Life Sciences Investors Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

abrdn Life Sciences Investors (HQL) Competitors

HQL vs. ETOR, RVT, TOP, TY, and USA

How does abrdn Life Sciences Investors compare to eToro Group?

Do insiders & institutionals believe in ETOR or HQL?

Which has more volatility & risk, ETOR or HQL?

Do analysts prefer ETOR or HQL?

Does the media prefer ETOR or HQL?

Is ETOR or HQL more profitable?

Which has better earnings and valuation, ETOR or HQL?

Summary

How does abrdn Life Sciences Investors compare to Royce Small-Cap Trust?

Which has more volatility and risk, RVT or HQL?

Do insiders and institutionals have more ownership in RVT or HQL?

Is RVT or HQL a better dividend stock?

Which has better earnings & valuation, RVT or HQL?

Does the media refer more to RVT or HQL?

Is RVT or HQL more profitable?

Summary

How does abrdn Life Sciences Investors compare to TOP Financial Group?

Do analysts recommend TOP or HQL?

Does the media prefer TOP or HQL?

Do insiders and institutionals hold more shares of TOP or HQL?

Which has stronger earnings and valuation, TOP or HQL?

Is TOP or HQL more profitable?

Which has more risk & volatility, TOP or HQL?

Summary

How does abrdn Life Sciences Investors compare to Tri Continental?

Is TY or HQL a better dividend stock?

Which has better earnings and valuation, TY or HQL?

Do insiders and institutionals believe in TY or HQL?

Which has more risk & volatility, TY or HQL?

Does the media prefer TY or HQL?

Is TY or HQL more profitable?

Summary

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

Does the media refer more to HQL or USA?

Which has higher valuation & earnings, HQL or USA?

Do insiders and institutionals have more ownership in HQL or USA?

Is HQL or USA more profitable?

Which has more risk and volatility, HQL or USA?

Is HQL or USA a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQL vs. The Competition

abrdn Life Sciences Investors Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools